# Julien Mazières
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/julien-mazieres/
## Facts
| Field | Value |
| --- | --- |
| Citations | 49,711 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 91 |
| i10-index | 313 |
| Last Known Institution | Université Toulouse III - Paul Sabatier |
| OpenAlex ID | https://openalex.org/A5055246540 |
| ORCID iD | 0000-0002-5921-7613 |
| Works | 995 |
## Researcher papers
Showing 12 of 31.
- [Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial](https://scholariq.org/papers/erlotinib-versus-standard-chemotherapy-as-first-line-treatment-for-european/)
- [Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-for-squamous-non-small-cell-lung-cancer/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-untreated-brafv600e/)
- [First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer](https://scholariq.org/papers/first-line-lorlatinib-or-crizotinib-in-advanced-i-alk-i-positive-lung-cancer/)
- [Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-i-her2-i-mutant-non-small-cell-lung-cancer/)
- [Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)](https://scholariq.org/papers/routine-molecular-profiling-of-patients-with-advanced-non-small-cell-lung-cancer/)
- [Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/bevacizumab-for-newly-diagnosed-pleural-mesothelioma-in-the-mesothelioma-avastin/)
- [Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer](https://scholariq.org/papers/association-of-the-lung-immune-prognostic-index-with-immune-checkpoint-inhibitor/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)
- [Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
## Researcher university
- [Université Toulouse III - Paul Sabatier](https://scholariq.org/institutions/universite-toulouse-iii-paul-sabatier/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.